Biogen

Biogen is an American global biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.

History

Biogen was founded in 1978 in Geneva by several prominent biologists, including Kenneth Murray of the University of Edinburgh, Phillip Allen Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who served as CEO during the start-up phase) and Charles Weissmann, University of Zurich (who contributed the first product interferon alpha). Gilbert and Sharp were subsequently honored with Nobel Prizes: Gilbert was recognized in 1980 with the Nobel Prize in Chemistry for his work in understanding DNA sequencing, while Sharp received the Nobel Prize in Physiology or Medicine in 1993 for his discovery of split genes.

In 2003, Biogen merged with San Diego, California-based IDEC Pharmaceuticals (formed in 1986 by biotech pioneers Ivor Royston and Howard Birndorf) and adopted the name Biogen Idec. After the merge, Biogen Idec became the 3rd largest Biotechnology company in the world. Following shifts in research core areas, the company has since shortened its name, reverting to simply Biogen.

Podcasts:

PLAYLIST TIME:

Latest News for: biogen

Edit

European regulators OK Alzheimer's treatment Leqembi after initial doubts

Newsday 16 Apr 2025
The infused treatment from Japanese drugmaker Eisai and Biogen received approval for patients in early stages of the fatal, mind-robbing disease ... Those include brain bleeding and swelling, which can be dangerous in rare cases ... Sign up ... Newsday ... 2.17 ... ....
Edit

European Commission Grants Marketing Authorization for Leqembi® (lecanemab) (Biogen Inc)

Public Technologies 15 Apr 2025
) ... A link to the press release from the European Commission is available here. Eisai and Biogen will issue a full press release on the approval this evening ... Biogen Inc.
Edit

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission (Biogen Inc)

Public Technologies 14 Apr 2025
Haruo Naito, "Eisai") and Biogen Inc ... Biogen Inc ... public.affairs@biogen.com ... Biogen Inc ... IR@biogen.com ... About the Collaboration between Eisai and Biogen for AD ... About Biogen ... Follow Biogen on social media - Facebook , LinkedIn , X , YouTube .
Edit

Five things to know: Silk innovation, a tech lease, Biogen R&D and the Best Places ...

Business Journal 09 Apr 2025
Good morning, Boston ... silkworms. You won't believe what their silk can be used for ... Hundreds of law… .
Edit

Boston Faces Identity Crisis Amid Trump’s Cuts to University and Research Funding

New York Times 06 Apr 2025
Colleges and teaching hospitals are the cornerstones of the city’s economy — and identity. But federal funding cuts to higher education could change that ... .
  • 1
×